Okyo Pharma Ltd. (OK11)
XMUN 
Summary
OK11 Chart
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is a chronic, nerve-related ocular condition that currently has no US Food and Drug (FDA)-approved treatments.
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showing greater than 80% pain reduction after 12 weeks of treatment. Patients treated with the 0.05% formulation of urcosimod saw a statistically significant reduction in pain scores compared to baseline, as measured by the Visual Analogue Scale (VAS), with an average improvement of 5.5 points versus 2.75 in the placebo group.
Okyo Pharma Ltd. Dividends
Okyo Pharma Ltd. Earnings
| 12 Aug 2025 (In 1 day) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 Date | | - Cons. EPS | - EPS |
| 2 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Sep 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 (In 1 day) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 Date | | - Cons. EPS | - EPS |
| 2 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Sep 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
Okyo Pharma Ltd. (OK11) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Okyo Pharma Ltd. ever had a stock split?
Okyo Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Gary S. Jacob CEO | XMUN Exchange | US6793451088 ISIN |
| GB Country | 3 Employees | - Last Dividend | - Last Split | 17 May 2022 IPO Date |
Overview
OKYO Pharma Limited is a clinical-stage biopharmaceutical company based in the United Kingdom, dedicated to the development of innovative therapeutics for patients afflicted with inflammatory eye diseases and ocular pain. The company, founded in 2007 and headquartered in London, has taken significant strides in the biopharmaceutical field, particularly focusing on conditions that affect eye health. With a strong commitment to addressing unmet medical needs, OKYO Pharma is at the forefront of researching and developing advanced treatments that promise to alleviate suffering and improve the quality of life for patients facing eye-related afflictions.
Products and Services
- OK-101
This lead preclinical product candidate is currently in Phase II clinical trials and represents OKYO Pharma’s pioneering approach to treating dry eye disease. Dry eye disease is a prevalent condition that can significantly impact an individual's quality of life, causing discomfort, and in severe cases, impairing vision. OK-101 is being developed with the aim of providing a novel, effective treatment option for patients who suffer from this condition, potentially improving their symptoms and overall eye health.
- OK-201
Another innovative venture by OKYO Pharma, OK-201 is a preclinical analogue candidate derived from bovine adrenal medulla. This lipidated-peptide is being developed for the treatment of neuropathic chronic pain, a condition that remains challenging to manage with current treatment options. By focusing on novel pathways and mechanisms, OKYO Pharma aims to contribute an important solution to the field of pain management, particularly for patients whose quality of life is severely affected by chronic pain conditions.
Contact Information
